Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Erica Isaacson"'
Publikováno v:
JAIDS Journal of Acquired Immune Deficiency Syndromes. 33:15-21
To study the potential development of genotypic and phenotypic resistance to tenofovir disoproxil fumarate (tenofovir DF) when used as a part of a 96-week HIV-1 treatment regimen for antiretroviral treatment-experienced HIV-infected patients.Clinical
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca102b19c450d0d57a0a32bf4baeaca3
https://doi.org/10.1097/00126334-200305010-00003
https://doi.org/10.1097/00126334-200305010-00003
Autor:
Harry Lampiris, Shan-Shan Chen, Peter Ruane, Robert A. Myers, Study Team, Michael D. Miller, Andrew K. Cheng, Robert T. Schooley, Daniel S Berger, Erica Isaacson, Gildon N. Beall
Publikováno v:
AIDS. 16:1257-1263
OBJECTIVE To evaluate the safety and efficacy of once daily doses of tenofovir DF (TDF) administered in combination with other antiretroviral therapy (ART) in treatment-experienced HIV-1-infected patients with incomplete virological suppression. DESI
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c045c9d0d9a1d5754553b965dee0c92
https://doi.org/10.1097/00002030-200206140-00008
https://doi.org/10.1097/00002030-200206140-00008
Autor:
Nicolas A. Margot, Ian McGowan, Andrew K. Cheng, Erica Isaacson, Robert T. Schooley, Michael D. Miller
Publikováno v:
AIDS (London, England). 16(9)
Objective To evaluate the virologic responses and mutational profiles in antiretroviral-experienced patients adding tenofovir DF once-daily to their existing regimens. Design Resistance analyses were performed for patients in a phase II placebo-contr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::516f1c3a42aa1066af63d81050d8abd6
https://pubmed.ncbi.nlm.nih.gov/12045487
https://pubmed.ncbi.nlm.nih.gov/12045487